Newborn; Infection

Newborn Sepsis

Addition of C-reactive protein test for management strategies to follow-up febrile neonates in outpatient.

C reactive protein

Sisli Etfal Education and Research Hospital

New Protocol for Febrile Neonate Management

New Protocol for Identification of Serious Bacterial Infection in Febrile Newborn

All febrile neonate admitted and evaluated for SBI. An episode of SBI was defined as (A) the growth of a known pathogenic bacteria in one or more of cultures (bacteremia, meningitis, osteomyelitis, suppurative arthritis, urinary tract infection, bacterial enteritis, and pneumonia), (B) any disease commonly associated with bacterial pathogens including pneumonia, acute otitis media, suppurative arthritis, osteomyelitis, and soft-tissue infections (cellulitis, abscess, mastitis, and omphalitis). Pneumonia was defined as a new discrete infiltration on the chest film, which was confirmed by an attending pediatric radiologist with the presence of typical clinical signs and symptoms.

All infants were classified at low-risk by the criteria of Rochester, Boston, Philadelphia and new created Sisli Etfal protocols.

Ali Bulbul

Associate professor

Sisli Hamidiye Etfal Training and Research Hospital

Secondary (AA) Amyloidosis

Rheumatoid Arthritis

Nephrotic Syndrome

Familial Mediterranean Syndrome

Kidney Diseases

Gastrointestinal Diseases

NC-503 (Anti-amyloidotic (AA) Agent)

Indiana University School of Medicine, Department of Pathology and Laboratory Medicine,

Boston Medical Center, Renal Division

Mayo Clinic

Mount Sinai Medical Center

Rheumatism Foundation Hospital

Centre Hospitalier du Mans, Service de Rhumatologie

Hôpital Claude Huriez, Service de médecine Interne, Clinique Médicale A

Hôpital Cochin, Centre de Recherche et d'Explorations Fonctionnelles

Bnai Zion Medical Center

Heller Institute of Medical Research, Sheba Medical Center

Italian Group for Systemic Amyloidosis, Biotechnology Research Laboratories, IRCCS Policlinico San Matteo, Internal Medicine and Medical Oncology

Vilnius University Hospital

University Hospital Groningen, Department of Medicine, Division of Rheumatology

Instytut Reumatologiczny

Okregowy Szpital Kolejowy, Zaklad Reumatologii

Institute of Rheumatology RAMS

Regional Hospital No. 1

Hospital Universitario Germans Trias I Pujol, Servicio de Reumatologia

Hospital Clinic I Provincial de Barcelona, Jefe del Departamento de Reumatologia

Ciutad Sanitària y Universitària de Bellvitge, Servicio de Reumatologia, Hospitalet de Llobregat

Hospital Clinico San Carlos de Madrid, Servicio de Reumatologia

Cerrehpasa Tip Fakultesi

Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology

Marmara University Medical School Hospital, Department of Rheumatology

Royal Free and University College Medical School, Department of Medicine, National Amyloidosis Centre

Gartnavel General Hospital

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

A Phase II/III Study of the Safety and Efficacy of NC-503 in Patients Suffering From Secondary (AA) Amyloidosis

osteomyelitis/ripuli

New Protocol for Febrile Neonate Management

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Täydellisin lääketieteellinen tietokanta tieteen tukemana